An NIH-funded partnership between Johns Hopkins and Howard University speeds the development of medical devices addressing ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Vertex Pharmaceuticals is marching beyond its cystic fibrosis stronghold with bold steps into pain management and genetic ...

Vertex is among previous investors in Arbor’s just-completed Series C as well as earlier rounds, though Arbor wholly owns its pipeline candidates, Smith said. Joining Vertex were funds managed ...

A court in North Dakota has found Greenpeace liable for hundreds of millions of dollars over actions to combat the Dakota Access Pipeline. The environmental organization will be liable for about $ ...

Vertex Pharmaceuticals Incorporated ... including ALYFTREK for CF patients and JOURNAVX for acute pain. These products, along with its robust pipeline, which includes four pivotal development ...